CENTER VALLEY, Pa., Feb. 28, 2019 /PRNewswire/ — Aesculap Biologics, LLC (“Aesculap Biologics”) announced today that it has successfully achieved 50 percent enrollment in the ongoing Phase 3 clinical trial of NOVOCART® 3D, an autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee. To date, approximately 117 of the expected 233 study participants have been …